These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 21278067

  • 1. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.
    Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, Koopman-Keemink Y, Gorter SL, Raat H, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2011 Jun; 50(6):1131-6. PubMed ID: 21278067
    [Abstract] [Full Text] [Related]

  • 2. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [Abstract] [Full Text] [Related]

  • 3. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis.
    Haapasaari J, Kautiainen HJ, Isomäki HA, Hakala M.
    J Rheumatol; 2004 Nov; 31(11):2286-9. PubMed ID: 15517646
    [Abstract] [Full Text] [Related]

  • 4. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
    van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM.
    J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 6. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
    [Abstract] [Full Text] [Related]

  • 7. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
    Otten MH, Prince FH, Twilt M, van Rossum MA, Armbrust W, Hoppenreijs EP, Kamphuis S, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Ten Cate R, van Suijlekom-Smit LW.
    J Rheumatol; 2010 Mar; 37(3):665-7. PubMed ID: 20080910
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group.
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [Abstract] [Full Text] [Related]

  • 9. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy of etanercept in the treatment of juvenile idiopathic arthritis].
    de Inocencio Arocena J, Merino Muñoz R, Alvarez Madrid C, García-Consuegra Molina J.
    An Pediatr (Barc); 2009 Apr; 70(4):354-61. PubMed ID: 19324597
    [Abstract] [Full Text] [Related]

  • 11. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
    Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
    [Abstract] [Full Text] [Related]

  • 12. The German etanercept registry for treatment of juvenile idiopathic arthritis.
    Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A, Paediatric Rheumatology Collaborative Group.
    Ann Rheum Dis; 2004 Dec; 63(12):1638-44. PubMed ID: 15115709
    [Abstract] [Full Text] [Related]

  • 13. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
    Sevcic K, Orban I, Brodszky V, Bazso A, Balogh Z, Poor G, Kiss E.
    Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
    Borte S, Liebert UG, Borte M, Sack U.
    Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 17. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V, Horneff G.
    Rheumatology (Oxford); 2011 Jan 07; 50(1):214-21. PubMed ID: 21148155
    [Abstract] [Full Text] [Related]

  • 18. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept.
    Yazdani C, McLaughlin T, Cummins G, Doyle J.
    Am J Manag Care; 2001 Sep 07; 7(13 Suppl):S419-26. PubMed ID: 11594238
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G, Lindgren P, Singh A, Klareskog L.
    Ann Rheum Dis; 2005 Aug 07; 64(8):1174-9. PubMed ID: 15708879
    [Abstract] [Full Text] [Related]

  • 20. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
    Schmeling H, Horneff G.
    Rheumatology (Oxford); 2005 Aug 07; 44(8):1008-11. PubMed ID: 15855187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.